Allergan’s Commitment to Research and Development Pushes Forward

Allergan’s Commitment to Research and Development Pushes Forward

December 15, 2014
By Carolynn Grimes
The Plastic Surgery Channel

Heading into the New Year, the CEO’s of Allergan and Actavis say there will be virtually no change in Allergan’s commitment to its customers, physicians, and research and development.

 

Both companies are well run businesses that have a strong commitment to innovation and research and development.  Allergan, maker of Botox, recently agreed to be acquired for $66 billion by Actavis, who makes generic and brand-name medicines. Combining Actavis and Allergan will create one of the 10 largest global drug makers, with more than $20 billion expected in revenue next year.

Actavis CEO and President, Brent Saunders, said they would keep spending on R&D, contrasting to Valeant Pharmaceutical’s pledges to reduce research spending by 90% during their hostile takeover attempt earlier this year.  “We were very concerned about what Valeant would have done to Allergan and I think the most dramatic statement was their wanting to reduce our R & D budget by 90%. They would have come in here and basically destroyed everything except very late stage clinical development,” said David Pyott, CEO of Allergan.

Saunders said research and development is the lifeblood of Actavis, which is good news for customers and physicians who were concerned a buyout would mean an end to physician education and customer service.

Continuing a Great Track Record with the Plastic Surgery Community

wp1As the two companies entered into discussions, it became clear Actavis’ values are very similar to those of Allergan. The latter has always had close ties to the entire network of patient care, from supporting medical education to being a strong supporter of the medical societies.

“We have tremendous focus on the customer and not just the customer in the simplest of sense where we call on a doctor’s office and supply them with samples and provide them with information, but much, much broader than that,” said Pyott.

Job Cuts in the Forecast

“Our commitment to our customers and our plastic surgeons will be unwavering,” said Saunders.  “You should notice no change, and hopefully over time a stronger commitment from the combined companies. While both Pyott and Saunders are positive about the acquisition, there will be changes in staff within the two companies.  “While Brent (Saunders) and I are very open with our teams, we tell them, when mergers and acquisitions occur there has to be reductions of duplicate spending,” said Pyott.

 

Click to add a comment

More in

Hair today, gone tomorrow - today's best lasers.

Hair Today, Gone Tomorrow – Today’s Best Lasers

Dawn TongishJune 23, 2017
Can Cankles be Solved with Plastic Surgery?

Can Cankles be Solved with Plastic Surgery?

John HammarleyJune 22, 2017
Labiaplasty 101: Looking Normal 'Down There'

Labiaplasty 101: Looking Normal ‘Down There’

Dawn TongishJune 21, 2017
Ransomware and plastic surgery patient privacy.

Ransomware and Plastic Surgery Patient Privacy

Jason Pozner, MDJune 20, 2017

Cosmetic Surgery for Teens and Pre-Teens?

Jason Cooper, MDJune 19, 2017

The Difference Between Liposuction & Liposculpture

Anne MeyerJune 19, 2017
Understanding the trend of buttock fat grafting deaths.

Understanding the Trend of Buttock Fat Grafting Deaths

Jason Pozner, MDJune 16, 2017
A mommy makeover for mothers of multiples.

A Mommy Makeover for Mothers of Multiples

Anne MeyerJune 15, 2017
In Surgery, What is Your Plastic Surgeon and Team Listening To?

In the OR, What Music is Your Surgeon and Team Listening To?

John HammarleyJune 14, 2017